{rfName}
A

Indexed in

License and use

Citations

2

Altmetrics

Analysis of institutional authors

Share

Publications
>
Article

A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.

Publicated to:Blood. - 2025-03-16 (), DOI: 10.1182/blood.2024025440

Authors: Falgàs A; Lázaro-Gorines R; Zanetti SR; Rubio-Pérez L; Martinez-Moreno A; Vinyoles M; Guerrero-Murillo M; Fernandez-Fuentes N; Roca-Ho H; Tirado N; Panisello C; Velasco-Hernandez T; Mayado A; Pérez-Pons A; Genesca E; Ribera JM; Ribera J; Camos M; Ramírez-Orellana M; Anguita E; Ballerini P; Fuster JL; Juan M; González-Navarro EAA; Locatelli F; Stam RWW; Querol S; Velasco P; Ortiz-Maldonado V; Martínez-Cibrian N; Delgado J; Orfao A; Alvarez-Vallina L; Bueno C; Menendez P

Affiliations

Bambino Gesù Children's Hospital, Roma, Italy. - Author
Centro de Investigación del Cáncer (IBMCC-CSIC/USAL and IBSAL),Biomedical Research Networking Centre Consortium of Oncology (CIBERONC) (CB16/12/00400), Instituto de Salud Carlos III, Salamanca, Spain. - Author
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain. - Author
Department of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain. - Author
Fundació Internacional Josep Carreras, Barcelona, Spain. - Author
Hopital A. TROUSSEAU, Sorbonne Université, AP-HP, Paris, France. - Author
Hospital Clinic de Barcelona, Barcelona, Spain. - Author
Hospital Clinic, Barcelona, Spain. - Author
Hospital Clínico Universitario Virgen de la Arrixaca. Instituto Murciano de Investigación Biosanitaria (IMIB), Pilar de la Horadada. Alicante, Spain. - Author
Hospital Sant Joan de Déu, Barcelona, Spain. - Author
Hospital Universitario 12 de Octubre, Madrid, Spain. - Author
ICO-Hospital Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras, Badalona, Spain. - Author
IJC, Barcelona, Spain. - Author
Institut Català d'Oncologia-Hospital Germans Trias i Pujol. Josep Carreras Research Institute. Badalona. Universitat Autònoma de Barcelona, Badalona, Spain. - Author
Josep Carreras Leukaemia Research Institute, Badalona, Spain. - Author
Josep Carreras Leukaemia Research Institute, Barcelona, Spain. - Author
Josep Carreras Leukaemia Research Institute, Department of Biomedicine, School of Medicine,, Barcelona, Spain. - Author
Josep Carreras Leukemia Research Institute, Barcelona, Spain. - Author
Josep Carreras Leukemia Research Institute., Barcelona, Spain. - Author
Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands. - Author
Spanish National Cancer Reserach Centre (CNIO), Madrid, Spain. - Author
University Complutense, Madrid, Spain. - Author
University Hospital Vall d´Hebron, Barcelona, Spain. - Author
University of Barcelona, Barcelona, Spain. - Author
University of Salamanca, Salamanca, Spain. - Author
University of Salamanca. Cancer Research Center (IBMCC, USAL-CSIC) and IBSAL, Salamanca, Spain. - Author
See more

Abstract

Keywords

Astronomia / físicaBiochemistryBiodiversidadeBiotecnologíaCell biologyCiências ambientaisCiências biológicas iCiências biológicas iiCiências biológicas iiiEngenharias ivFarmaciaGeneral medicineHematologyImmunologyInterdisciplinarMedicina iMedicina iiMedicina iiiSaúde coletiva

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Blood due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2025, it was in position 2/97, thus managing to position itself as a Q1 (Primer Cuartil), in the category Hematology. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-07-01:

  • Scopus: 2

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-01:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 9.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 9 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 213.1.
  • The number of mentions on the social network X (formerly Twitter): 20 (Altmetric).
  • The number of mentions in news outlets: 26 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: France; Italy; Netherlands.